title: Impact of infusion method on amikacin serum levels in humans.
authors.affiliation: Biopharmacy, Galenic and Hospital Pharmacy Department EA 4034, Lille Nord de France University, France.
authors.forename: N
authors.initials: N
authors.lastname: Simon
authors.forename: B
authors.initials: B
authors.lastname: Décaudin
authors.forename: D
authors.initials: D
authors.lastname: Lannoy
authors.forename: M F
authors.initials: MF
authors.lastname: Odou
authors.forename: M
authors.initials: M
authors.lastname: De Broucker
authors.forename: C
authors.initials: C
authors.lastname: Barthélémy
authors.forename: E
authors.initials: E
authors.lastname: Poret
authors.forename: L
authors.initials: L
authors.lastname: Dubreuil
authors.forename: P
authors.initials: P
authors.lastname: Odou
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000583:Amikacin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001424:Bacterial Infections / Q000188:drug therapy*; D017714:Community-Acquired Infections / Q000188:drug therapy*; D005260:Female; D006207:Half-Life; D006801:Humans; D007260:Infusion Pumps; D007262:Infusions, Intravenous; D008171:Lung Diseases / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014018:Tissue Distribution
chemical_list: D000900:Anti-Bacterial Agents; D000583:Amikacin